Capricor Therapeutics, Inc.

4.74 USD
+0.04 (+0.85%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

Capricor Therapeutics, Inc. stock is down -20.87% since 30 days ago. The next earnings date is Aug 5, 2024. The company has had above-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 47.37% of the previous 22 June’s closed higher than May. In the last 4 Unusual Options Trades, there were 4 PUTs.

Options Flow Last 10
Date & Time Expiration Date Strike Price Trade Type Size Open Interest
04 Jun 18:23 17 Jan, 2025 5.00 PUT 2007 10
04 Jun 18:23 17 Jan, 2025 5.00 PUT 200 10
04 Jun 18:52 17 Jan, 2025 7.50 PUT 296 0
04 Jun 18:53 17 Jan, 2025 7.50 PUT 100 0

About Capricor Therapeutics, Inc.

Capricor Therapeutics, Inc. focuses on the development of transformative cell and exosome-based therapeutics. Its lead candidate, CAP-1002, an allogeneic cardiac-derived cell therapy, has completed phase III clinical trial for the treatment of patients with late-stage Duchenne muscular dystrophy (DMD) The company also develops CAP-2003 that is in pre-clinical development for the. treatment of trauma related injuries and conditions; and two vaccine candidates, which are in development stage for the potential prevention of COVID-19.